477872-93-8 Usage
Molar mass
253.7 g/mol (the mass of one mole of the compound)
Thiazole derivative
(a compound that is derived from thiazole, a five-membered ring system with one sulfur and one nitrogen atom)
Carboxylic acid group
(a functional group in the compound with a carboxyl group (-COOH))
Chlorobenzyl substituent
(a chlorine atom attached to a benzyl group (-CH2-Ph) that is attached to the thiazole ring)
Pharmacological properties
(the potential for the compound to have therapeutic effects, such as antimicrobial and anticancer activities)
Organic synthesis
(the process of creating new compounds from simpler molecules, the compound may have potential applications in this field)
Medicinal chemistry
(the study of the properties and uses of compounds in the development of new drugs, the compound may have potential use in this field)
Chlorobenzyl group
(an important structural feature of the compound that contributes to its biological activities)
Thiazole core
(an important structural feature of the compound that contributes to its biological activities and potential use in pharmaceutical research)
Check Digit Verification of cas no
The CAS Registry Mumber 477872-93-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,7,8,7 and 2 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 477872-93:
(8*4)+(7*7)+(6*7)+(5*8)+(4*7)+(3*2)+(2*9)+(1*3)=218
218 % 10 = 8
So 477872-93-8 is a valid CAS Registry Number.
477872-93-8Relevant academic research and scientific papers
Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor
Jung, Hui Jin,Nam, Eun Hye,Park, Jin Young,Ghosh, Prithwish,Kim, In Su
, (2021/02/26)
Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.
